It’s All About Abecma As 2seventy Sells Off Pipeline To Regeneron In Restructuring

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The cell therapy biotech will reduce its headcount from 280 to 65, with most of them – including two execs – going to Regeneron, which is paying just $5m up front to become a cell therapy player.

• Source: Shutterstock

2seventy Bio, Inc. is taking a small initial payment to sell off its cell therapy pipeline to Regeneron Pharmaceuticals, Inc. amid a restructuring that is designed to allow the company to focus on its one marketed product, the Bristol Myers Squibb Company-partnered multiple myeloma CAR-T therapy Abecma (idecabtagene vicleucel). Meanwhile, the deal gives Regeneron an opportunity to become a cell therapy player on top of its rapidly expanding presence in immuno-oncology.

The transaction announced on 30 January sharpens 2seventy’s focus on Abecma just ahead of a US Food and Drug Administration...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.